Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study
Related Articles
Innovating Clinical Trials for Amyotrophic Lateral Sclerosis: Challenging the Established Order
Development of effective treatments for amyotrophic lateral sclerosis (ALS) has been hampered by disease heterogeneity, a limited understanding of underlying pathophysiology, and methodologic design challenges.…
Modelling the cascade of biomarker changes in GRN-related frontotemporal dementia
Objective Progranulin-related frontotemporal dementia (FTD-GRN) is a fast progressive disease. Modelling the cascade of multimodal biomarker changes aids in understanding the aetiology of this disease…
Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis
Objective The clinical course of multiple sclerosis (MS) is variable and largely unpredictable pointing to an urgent need for markers to monitor disease activity and…
The PedsQL™ in Pediatric Patients with Duchenne Muscular Dystrophy: Feasibility, Reliability, and Validity of the Pediatric Quality of Life Inventory Neuromuscular Module and Generic Core Scales
Objective: To evaluate the reliability and validity of the PedsQL™ 3.0 Neuromuscular Module (NMM) in assessing health-related quality of life in the Duchenne muscular dystrophy…
English
العربية
简体中文
Nederlands
Français
Deutsch
Italiano
Português
Русский
Español
Responses